CME Group Inc. CME ← Back to all reports

CME Group Inc.

CME · Financials
B ★★★ Hold
Jul 26, 2026 · Score 82 · Type A — Value-style analysis Used for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety. Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology → $254.32
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses. $225.00 ($218.00–$232.00)
Target PriceOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology → $285.00
Expected Return
  • Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
  • A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Methodology →
+12.1%

Type A - CME Group Inc. (CME) 20260726 Stock Analysis

📅 CME Key Upcoming Events

🏢 Step 1: CME Company Overview & Business Model

Q1-A1. What is CME?

Q1-A2. How Does CME Make Money?

Q1-A3. CME’s Revenue Segments & Core Income Sources

Q1-A4. Who Are CME’s Competitors?

Q1-A5. CME Key Events: Past 12 Months

Q1-A6. Step 1 Key Takeaways

🏰 Step 2: CME’s Economic Moat, Growth & Capital Allocation

Q2-A1. Does CME Have a Durable Economic Moat?

Q2-A2. Is CME’s Growth Sustainable?

Q2-A3. How Does CME Allocate Capital & Return Cash?

Q2-A4. Step 2 Key Takeaways

💰 Step 3: Is CME Profitable? Financial Health Analysis

Q3-A2. How Profitable Is CME? (Margins & ROIC)

Q3-A3. What Drives CME’s Returns? (ROIC Breakdown)

Q3-A4. Are CME’s Earnings High Quality?

Q3-A5. Is CME’s Balance Sheet Healthy? (Debt & Leverage)

Q3-A6. Step 3 Key Takeaways

🔎 Step 4: CME Forensic Accounting & Dilution Review

Q4-A1. Does CME Have Accounting Red Flags?

Q4-A2. Is CME Overspending? (Capex & Capital Cycle)

Q4-A3. How Sound Is CME’s Cash Flow?

Q4-A4. Is CME Diluting Shareholders?

Q4-A5. Data Integrity Check

Q4-A6. Step 4 Key Takeaways

👔 Step 5: CME Management & Shareholder Alignment

Q5-A1. Can You Trust CME’s Management? (Guidance Track Record)

Q5-A2. What Are CME Insiders Doing?

Q5-A3. Is CME’s Management Aligned With Shareholders?

Q5-A4. Step 5 Key Takeaways

⛵ Step 6: CME Market Flow & Sentiment

Q6-A1. Analyst Consensus vs CME Guidance

Q6-A2. What Is CME’s Short Interest?

Q6-A3. Step 6 Key Takeaways

🚀 Step 7: CME Catalysts & Price Triggers

Q7-A1. What Could Move CME Stock? (Top 3 Catalysts)

Q7-A2. CME’s Earnings Revision Trend

Q7-A3. Step 7 Key Takeaways

⚖️ Step 8: Is CME Fairly Valued? Valuation Analysis

Q8-A1. CME’s Key Valuation Multiples (P/E, EV/EBITDA)

Q8-A2. CME vs Peers: Valuation Comparison

Q8-A3. Is CME Cheap or Expensive vs Its History?

Q8-A4. What Growth Is Priced Into CME? (Reverse DCF)

Q8-A5. Valuation Cross-Check

Q8-A6. CME’s Asset & Stake Valuation

Q8-A7. Final Valuation Adjustment

Q8-A8. Valuation Adjustment Score Calculation

💀 Step 9: What Are the Risks of CME? Fatal Risks & Pre-Mortem

Q9-A1. What Are the Biggest Risks to CME?

Q9-A2. How Sensitive Is CME to the Economy?

Q9-A3. CME Pre-Mortem: What Could Go Wrong?

Q9-A4. Risk Adjustment Score Calculation

🎯 Step 10: CME Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

Q10-A2. Should You Buy CME? (Recommendation)

Q10-A3. Investment Thesis in One Line

Q10-A4. CME’s Price Trend & Key Drivers

Q10-A5. Action Plan

🕵️‍♂️ Deep Dive Analysis

Q1: Is CME Group’s Lack of Perpetual Futures Its Biggest Weakness?

Q2: Can CME’s 21.6x Trailing P/E Be Justified by a Structural Shift in Interest Rate Volatility?

Q3: How Will the CEO Transition From Terry Duffy to Lynne Fitzpatrick Alter Corporate Strategy?

Q5: Can the FanDuel Prediction Market Joint Venture Successfully Combat Offshore Platforms?

Q6: Are CME’s Unparalleled Margin Efficiencies an Impenetrable Barrier Against Competitors?

Q7: How Does the Reinvestment of Clearinghouse Collateral Impact the Bottom Line?

Q8: Will the Google Cloud Migration Expose CME to Unacceptable Latency and Cybersecurity Risks?

Q9: Does the Sale of OSTTRA Signal a Retreat From Post-Trade Services?

Q10: How Vulnerable Is CME’s Agricultural Segment to Shifting Global Supply Chains?

CME Group Inc. (CME)

Rating History

  1. 2026-07-21 A 88
  2. 2026-07-26 B 82